Baird: Biomarin Pharmaceutical (BMRN.US) rating was downgraded from superior to market neutral, and the target price was adjusted from $104.00 to $72.00.
Baird：下调Biomarin Pharmaceutical(BMRN.US)评级，由优于大市调整至中性评级, 目标价由104.00美元调整至72.00美元。
Baird: Biomarin Pharmaceutical (BMRN.US) rating was downgraded from superior to market neutral, and the target price was adjusted from $104.00 to $72.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.